Project A.L.S. Teams Up with Eli Lilly to Find Drugs for ALS

Eli Lilly is partnering with Project A.L.S. in order to expand the pipeline of potential drugs for ALS. Under the agreement, Project A.L.S. will screen small molecules that were originally developed by Lilly to target pathways involved in cancer to see if these small molecules have any activity in blocking the toxicity associated with ALS. Prize4Life’s Scientific Advisory Board member Dr. Tom Maniatis along with Dr. Thomas Jessell, both professors at Columbia University and Project A.L.S. Research Advisory Board members, have identified that there is overlap between some of the inflammatory signaling pathways activated in cancer and in ALS. Hopefully this partnership will lead to the identification of potential new therapeutics for ALS.

Eli Lilly is partnering with Project A.L.S. in order to expand the pipeline of potential drugs for ALS. Under the agreement, Project A.L.S. will screen small molecules that were originally developed by Lilly to target pathways involved in cancer to see if these small molecules have any activity in blocking the toxicity associated with ALS. Prize4Life’s Scientific Advisory Board member Dr. Tom Maniatis along with Dr. Thomas Jessell, both professors at Columbia University and Project A.L.S. Research Advisory Board members, have identified that there is overlap between some of the inflammatory signaling pathways activated in cancer and in ALS. Hopefully this partnership will lead to the identification of potential new therapeutics for ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail